Literature DB >> 19481983

Patient-reported respiratory symptoms in cystic fibrosis.

C H Goss1, T C Edwards, B W Ramsey, M L Aitken, D L Patrick.   

Abstract

BACKGROUND: Cystic fibrosis (CF) specific patient-derived and reported symptom tools are critical steps toward evaluating the outcomes of new therapies for CF.
METHODS: We conducted 25 in-depth qualitative interviews using the Day Reconstruction Method and 9 cognitive interviews at two CF programs, the University of Washington and Seattle Children's Hospital and Regional Medical Center. The interviews were audio-recorded and transcribed, and then coded and analyzed for themes relating to pulmonary symptoms and related psychosocial impacts.
RESULTS: Six pulmonary symptoms were identified as central to CF: cough, sputum production, wheeze, chest tightness, difficulty breathing/shortness of breath, and fever. Emotional impacts included frustration, sadness/depression, irritability, worry, difficulty sleeping; while activity impacts included time spent sitting or lying down, reduction of usual activities, and missing school or work. In all, 8 symptom items, 4 emotional impacts items, and 4 activity impacts were selected for inclusion on a new daily diary. We also assessed triggers for seeking care.
CONCLUSIONS: Using a qualitative inductive methodology, we have obtained patient centered data regarding pulmonary symptoms and burdens and have created a novel patient reported outcome measure for CF. Future studies will assess the validity of the instruments.

Entities:  

Mesh:

Year:  2009        PMID: 19481983     DOI: 10.1016/j.jcf.2009.04.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  33 in total

1.  Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR.

Authors:  Scott H Donaldson; Beth L Laube; Timothy E Corcoran; Pradeep Bhambhvani; Kirby Zeman; Agathe Ceppe; Pamela L Zeitlin; Peter J Mogayzel; Michael Boyle; Landon W Locke; Michael M Myerburg; Joseph M Pilewski; Brian Flanagan; Steven M Rowe; William D Bennett
Journal:  JCI Insight       Date:  2018-12-20

2.  The Cystic Fibrosis Symptom Progression Survey (CF-SPS) in Arabic: A Tool for Monitoring Patient's Symptoms.

Authors:  Catherine Norrish; Mark Norrish; Uwe Fass; Majid Al-Salmani; Ganji Shiva Lingam; Fiona Clark; Hebal Kallesh
Journal:  Oman Med J       Date:  2015-01

3.  Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).

Authors:  Laura S Gold; Donald L Patrick; Ryan N Hansen; Christopher H Goss; Larry Kessler
Journal:  J Cyst Fibros       Date:  2019-05-22       Impact factor: 5.482

4.  Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.

Authors:  N Lechtzin; N West; S Allgood; E Wilhelm; U Khan; N Mayer-Hamblett; M L Aitken; B W Ramsey; M P Boyle; P J Mogayzel; C H Goss
Journal:  Contemp Clin Trials       Date:  2013-09-19       Impact factor: 2.226

5.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.

Authors:  Steven M Rowe; Sonya L Heltshe; Tanja Gonska; Scott H Donaldson; Drucy Borowitz; Daniel Gelfond; Scott D Sagel; Umer Khan; Nicole Mayer-Hamblett; Jill M Van Dalfsen; Elizabeth Joseloff; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2014-07-15       Impact factor: 21.405

6.  Life-space mobility is associated with frequency of hospitalization in adults with cystic fibrosis.

Authors:  Eric Raphael Gottlieb; Elisabeth Christine Smith; Linda Lucetta Wolfenden; Richard Mark Allman; Vin Tangpricha
Journal:  Clin Respir J       Date:  2010-10-01       Impact factor: 2.570

7.  Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.

Authors:  Jennifer Guimbellot; George M Solomon; Arthur Baines; Sonya L Heltshe; Jill VanDalfsen; Elizabeth Joseloff; Scott D Sagel; Steven M Rowe
Journal:  J Cyst Fibros       Date:  2018-04-21       Impact factor: 5.482

8.  Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Authors:  Sonya L Heltshe; Christopher H Goss; Valeria Thompson; Scott D Sagel; Don B Sanders; Bruce C Marshall; Patrick A Flume
Journal:  Thorax       Date:  2015-04-24       Impact factor: 9.139

Review 9.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

Review 10.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.